Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Hanny Al-Samkari et al, published in The New England Journal of Medicine:
“Romiplostim use allows more chemotherapy to be delivered on time.
A paper in this week’s New England Journal of Medicine by Hanny Al-Samkari and colleagues reports on a double-blind study of Romiplostim vs Placebo for Chemotherapy-induced Thrombocytopenia.
84% of the Romiplostim and 36% of the Placebo group had no chemotherapy dose modifications.
All the patients had solid tumours.
We do not know if administering more chemo results in a survival advantage, since this would have required a larger trial and much longer follow-up.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al‑Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article on The New England Journal of Medicine
Other articles featuring Michael Makris on Hemostasis Today.
-
Nov 2, 2026, 18:08Jonathan Penm: Antithrombotic Stewardship Optimizes VTE Prophylaxis in ICU Patients
-
Nov 2, 2026, 14:48Heghine Khachatryan: Vitamin B12 Replacement Choosing the Right Route for Each Patient
-
Nov 2, 2026, 14:28Anastasia Conti: ASH Global Research Award Backs New Directions in AML Research
-
Nov 2, 2026, 14:22Sara Zalghout: Linking Bacterial Virulence to NETosis and Thromboinflammation
-
Nov 2, 2026, 13:58Functional Iron Deficiency: From Iron Sequestration to Therapeutic Targeting
-
Nov 2, 2026, 13:56Jan Terje Andersen: Albumin Engineering Opens New Routes for Erythropoietin Delivery
-
Nov 2, 2026, 13:44Rishiraj Sinha: Strengthening ISBT–AABB Collaboration in Transfusion Medicine
-
Nov 2, 2026, 13:28Jeremiah Morris: Why Blood Detection Reagents Work Better on Dry Bloodstains
-
Nov 2, 2026, 12:38Maria Τektonidou: Machine Learning – A New Approach to CVD Risk in SLE